|
Previous Page | Residency Program Home Page
| Next Page
| A Message from the Interim Chair 
Adam P. Dicker, M.D., Ph.D.
Professor and InterimChairman
We welcome your inquiry into the Radiation Oncology Residency Program at Thomas Jefferson
University Hospital. Our program has a strong record of educating outstanding radiation oncologists.
We accomplish this by creating the best possible training environment, and here are some reasons
why I believe that you will find an exceptional learning atmosphere at Jefferson.
The oncology program throughout Jefferson has gained wide national recognition. It has
historically been a leader in the areas of organ preservation in breast cancer and colorectal cancer,
and it has helped to pioneer hyperthermia and intraoperative radiotherapy. Over the last several
years, we have gained prominence in neuro-oncology, 3D conformal radiation, and clinical trial
development.
As part of the Jefferson Health System (JHS), our department sees a large and varied patient
group. We launched major clinical programs and have witnessed a significant increase in clinical
activity. Our department delivers first-rate cancer care at its acclaimed Bodine Center for Cancer
Treatment, at Jefferson's Hospital for Neuroscience as well as Methodist Hospital Division's Radiation
Oncology Center and at our affiliate centers located at Riddle, Frankford, and Lower Bucks Hospitals.
We also participate in the Gamma Knife Unit and dedicated linear accelerator-based
Radiosurgery programs at Jefferson Hospital for Neuroscience. The multidisciplinary effort with
Jefferson's Department of Neurosurgery uses innovative approaches to such diverse Neurologic problems
as primary and secondary CNS tumors, movement disorders, pain syndromes, vascular malformations and
paraorbital tumors. These units complete a substantial investment at Jefferson in the neuro-oncology
disciplines.
Our department holds a number of important leadership positions within the Radiation
Therapy Oncology Group and is among the leading accruers to radiation oncology-oriented clinical
trials in the nation.
Our department members are also active in other national oncology cooperative groups,
including the Gynecologic Oncology Group (GOG) and Eastern Cooperative Oncology Group (ECOG).
Our department is leading many Jefferson clinical trials in areas such as tumors of the
brain, rectum, lung, prostate, and esophagus. The annualized funding from outside sources of research
within the department is $4.5 million, with applications recently submitted for support totaling $11.7
million.
Our radiation oncologists sub-specializing in particular tumor sites and organ systems are
achieving increasing success with difficult tumors, in part through carefully combined and sequenced
therapies enlisting the help of surgeons and medical oncologists. In addition to a sizable core of
patients who realize palliation or resolution of their cancers through radiation therapy, other
patients are benefiting from implanted radioactive seeds, radiation during surgery, or tissue heating
as a cancer-killing modality. In our department's modern, computerized facilities, treatment
strategies are made more precise through the input and research of the department's staff of radiation
biologists and medical physicists.
With these developments, our department has stepped further into the forefront of its field.
Our four-year residency program is accredited for eight residency positions and one clinical fellowship
position. We accept two new residents each July. Maintaining excellence in this program is one of the
primary means by which we improve the standard of care for cancer patients. I hope you will find our
program to be of interest to you. |
Previous Page | Residency
Program Home Page | Next Page
|
